Electromed (ELMD) Investor presentation summary

Company overview and market position

• Focuses on airway management devices to improve respiratory health and quality of life.

• Headquartered in Minnesota, with 174 employees and $57.1M annual revenue as of 9/30/2024.

• Operates in the large, expanding airway clearance market, primarily serving homecare patients.

• SmartVest system uses HFCWO technology, supported by clinical outcomes and strong reimbursement.

• Maintains a direct-to-patient model, driving high gross margins and robust cash flow.

Market opportunity and growth

• U.S. bronchiectasis market is underpenetrated, with only ~15% HFCWO penetration among diagnosed patients.

• Diagnosed bronchiectasis population is growing at ~12% annually, with 4.1 million estimated undiagnosed cases.

• Revenue breakdown: 94% from homecare, 51% from Medicare, and 73% from bronchiectasis patients.

• Growth strategy includes sales force expansion, increased marketing, and improved diagnosis rates.

• Long-term objectives target double-digit revenue growth and operating margin improvement.

Product features and clinical evidence

• SmartVest Clearway offers a lightweight, portable design and intuitive interface for better adherence.

• SmartNotes provides physicians with patient progress and therapy utilization data.

• Clinical studies show SmartVest reduces hospitalizations by 59%, antibiotic use by 57%, and ER visits by 75%.

• 97% of patients report feeling better or the same after use; 95% would recommend SmartVest.

• Well-established reimbursement code and broad payor coverage in the U.S.